Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Family-based Screening and Treatment of Helicobacter Pylori:A Real World Study

11 oktober 2021 uppdaterad av: Yanqing Li, Shandong University
The habit of family meals makes the infection rate of Helicobacter pylori high in China, which is also the main cause of reinfection of Helicobacter pylori. Eating together can easily cause family members to be infected with Helicobacter pylori. We used a real-world study to understand the risk factors, epidemiological characteristics, and safety and effectiveness of eradication therapy for helicobacter pylori infection in family-based screening and treatment.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

Helicobacter pylori infection is a worldwide problem, which is the main cause of gastric cancer. The habit of sharing meals in the family is one of the factors contributing to the high infection rate of HP in China, as well as the main cause of reinfection of HP. Sharing meals can easily cause family members to be infected with HP.Family members live together, eat together, share tableware and other behaviors through the "mouth to mouth" transmission of Helicobacter pylori may be infected with each other, is also one of the reasons for the eradication of many patients after re-infection.At the same time, repeated infection and treatment of Helicobacter pylori will increase the difficulty of Helicobacter pylori reeradication.As a family unit, to study the status of our country family helicobacter pylori infection, epidemiological characteristics, infection risk factor, the different schemes, such as the safety and efficacy of treatment to take measures to reduce the infection rate is of great significance to prevention and treatment of gastric cancer.

Studietyp

Observationell

Inskrivning (Förväntat)

400

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Li Yueyue, PhD
  • Telefonnummer: 18560089751
  • E-post: lyynqj@126.com

Studieorter

    • Shandong
      • Jinan, Shandong, Kina, 250012
        • Rekrytering
        • Department of Gastroenterology,Qilu Hospital,Shandong University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

3 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Community population aged above 3 years in family unit,The family unit is determined by actual living together rather than household registration relationship, with at least 2 people in the family and living together for at least 10 months each year in the past 5 years.

Beskrivning

Inclusion Criteria:

  • Community population over 3 years old who signed the informed consent.
  • at least 2 people in the family.
  • living together for at least 10 months each year in the past 5 years except child aged below 5.

Exclusion Criteria:

  • PPI drugs such as esomeprazole、pantoprazole、 rabeprazole,、lansoprazole、famotidine and H2 receptor antagonists were taken within two weeks.
  • antibiotics、bismuth agents or traditional Chinese medicine with antibacterial effect were taken within four weeks
  • There are other factors that researchers think are not suitable for participation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Familjebaserat
  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Family members in the study
Community groups that meet the inclusion criteria
Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient compliance of performing medical examination.
Tidsram: 1 year
Good compliance of medical examination advice was defined as the subjects took the medical advice given by the doctor and the rate of adoption and implementation of the medical examination advice.
1 year
Patient compliance of taking medication
Tidsram: 1 year
Patient compliance of taking medication is defined as the ratio of the actual dose of medication taken by the patient to the total amount of medication required by the prescription. Good medication compliance is defined as the ratio greater than 80%.
1 year
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tidsram: 1 year
Adverse reactions related to medication were recorded
1 year
Lesion detection ratio
Tidsram: 1 year
The lesion detection ratio was defined as the ratio of the number of subjects who underwent medical examination on the basis of doctor's recommendation and were finally diagnosed with lesion to the number of subjects who underwent examination.
1 year
Eradication rate
Tidsram: 1 year
Eradication rate was defined as the ratio of the number of patients diagnosed positive on the carbon 13 breath test to the number of subjects who turned negative after taking the eradication drug to the number of subjects diagnosed positive before taking the drug.
1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The high-risk factors of Helicobacter pylori infection in families were investigated by questionnaire statistics.
Tidsram: 1 year
Questionnaire survey was used to conduct information statistics on families undergoing Helicobacter pylori screening.Statistics include family members of the general situation, basic information, personal health and life habit, individual disease history, personal nearly 1 month medications, family health and lifestyle, family history, history of HP infection and the eradication of history, screening results, doctor give opinions and patient adherence and follow-up outcome after screening process, etc. Statistical soft ware was used to analyze factor correlations.
1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Li Yanqing, PhD, Qilu Hospital, Shandong University

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 juli 2021

Primärt slutförande (Förväntat)

1 maj 2022

Avslutad studie (Förväntat)

1 juni 2022

Studieregistreringsdatum

Först inskickad

25 juni 2021

Först inskickad som uppfyllde QC-kriterierna

29 juni 2021

Första postat (Faktisk)

9 juli 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 oktober 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 oktober 2021

Senast verifierad

1 oktober 2021

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2019SDU-QILU-186

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera